Yes I do have a clue and I understand the concept of frontloading based on steady state depot conc., I was thinking short-term high dose to achieve an immediate blood surge and that longer lasting esters don't cause this, my point was that even an ester with a 5-day half-life still causes an immediate peak in blood conc., after a single inj. Anyhow........
Front loading makes sense particularly if the cycle is relatively short. There are two ways to front load if the goal is to achieve steady state quickly (within the first week). For example, let’s assume someone was going to run a 12 week cycle of enanthate @ 1000 mg per week.
Steady state depot conc would take roughly 5 weeks to achieve, almost 10 weeks for absolute steady state with weekly inj, no front load. Therefore, blood conc are less than optimal for 1000 mg a week dosing until about 5 weeks into the cycle. Steady state conc., assuming a 5-d t½ at 1000 mg/wk would be about 1600 mg. If you want that steady state achieved quickly so blood levels are maximized, there are two ways to do it.
1) Front load with a single 1600 mg dose on day one, then weekly 1000 mg doses.
2) 1000 mg on day 1, 1000 mg on day 4, then 1000 mg on day 10, then weekly 1000 mg doses. This gets you to steady state by day 4.
The difference between the two protocols will likely be the peak conc of test, E2 and DHT in the blood at any given point in time. Some guys on this board seem to have a pretty specific threshold conc. for sides such as gyno and/or prostatitis. I would think there would be less of a surge of DHT and E2 with a tapering inj frequency up front vs a single high dose to front load. Either way, they both work out to the same steady state within the first 4-5 days.
Using the formula in the van der Vies paper, Acta Endocrinol 1985 suppl., if you know the half-life of the AAS you can set up the formula in Excel and figure out what front-load dose/protocol you want to use depending on how variable you want your blood levels to be during a cycle. You can alter steady state by altering inj frequency and/or dose.
W6